Advancing Molecular Diagnostics. Revealing Genomic Answers.

Backed by a strong IP portfolio, Rosetta Genomics' (NASDAQ:ROSG) scientists have developed proprietary platform technologies for the identification, extraction, quantification, and analysis of microRNAs from a wide range of sample types.

Founded in 2000, Rosetta Genomics' integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs.

 

LD Micro Main Event - December 6, 2016 at 2:30 p.m. EDT

Webcast Access for 90 days at http://wsw.com/webcast/ldmicro11/rosg

 


Ladenburg Thalmann 2nd Annual Healthcare Conference - September 27, 2016 at 8:30 a.m. EDT

Webcast Access for 90 days at http://wsw.com/webcast/ladenburg2/rosg

 

g

Corporate Presentations View All
Press Releases View All
Media & Information

Investor Relations & Media Contacts:

Anne Marie Fields

afields@lhai.com

Bruce Voss

bvoss@lhai.com
Press
Releases
Financial
Reports
SEC
Filings
Frequently
Asked Questions
Videos
Corporate
Governance
February 08, 2017
Rosetta Genomics Reports Preliminary RosettaGX Reveal™ Financial Results for the 2016 Fourth Quarter and Year

Rosetta Genomics Ltd. (NASDAQ: ROSG) announces preliminary financial results and unit growth for its RosettaGX Reveal™ (Reveal) assay for the classification of indeterminate thyroid nodules, for the three months and year ended December 31, 2016. Reiterates 2017 RosettaGX Reveal revenue guidance of between $4 million and $5 million as Company increases focus on the Reveal market opportunity.

February 06, 2017
Rosetta Genomics Announces Key U.S. Patent Allowances for Two RosettaGX Reveal microRNAs

Rosetta Genomics Ltd. (NASDAQ: ROSG) announces that the United States Patents and Trademark Office (USPTO) has granted two patent allowances for patent applications US 14/756,185 (‘185) and US 14/999,879 (‘879), both divisional patents of the parent application titled “microRNAs and uses thereof.” This strengthens the intellectual property surrounding the company’s novel thyroid nodule classifier and provides opportunities for IP monetization.

December 20, 2016
Rosetta Genomics Reports Third Quarter 2016 Financial Results

Rosetta Genomics Ltd. (NASDAQ: ROSG), a genomic diagnostics company that improves treatment decisions by providing timely and accurate diagnostic information to physicians, announces financial results for the three and nine months ended September 30, 2016.

November 23, 2016
Rosetta Genomics Announces Pricing of $5 Million Concurrent Registered Direct and Private Placement Offering

Rosetta Genomics announced it has entered into definitive agreements with one prominent institutional healthcare investor to purchase an aggregate of 1,095,000 ordinary shares at a purchase price per share of $0.50 and registered convertible debentures (convertible into 6,320,000 ordinary shares) in a registered direct offering, as well as unregistered convertible debentures (convertible into 2,585,000 ordinary shares) and warrants to purchase up to 10,000,000 ordinary shares in a concurrent private placement. The offering is expected to result in gross proceeds of approximately $5 million.

November 21, 2016
Rosetta Genomics Enters Research Collaboration using microRNA Biomarkers to Predict Response to Leading Immuno-Oncology Drug Nivolumab in Lung Cancer Patients

Rosetta Genomics announces that the Company has entered into a research agreement with Sheba Medical Center at Tel HaShomer, Israel, to develop a microRNA-based signature to predict response to Nivolumab, an immunotherapy drug marketed as Opdivo®, which is approved for the treatment of lung cancer patient.

October 27, 2016
Clinical Validation Study for RosettaGX Reveal Published in the Journal of Clinical Pathology

Rosetta Genomics announces that a clinical validation study in support of RosettaGX Reveal, the Company’s first-of-its-kind microRNA classifier for indeterminate thyroid nodules, has been published in the Journal of Clinical Pathology.

October 24, 2016
RosettaGX Reveal Analytical Validation Study Featured on the Cover of the October Issue of Cancer Cytopathology

Rosetta Genomics announces that an article highlighting the analytical validation data from a study of the Company’s novel, microRNA-based assay for the classification of indeterminate thyroid nodules is featured on the cover of the October issue of the peer-reviewed journal, Cancer Cytopathology.

October 20, 2016
Rosetta Genomics Appoints Mark R. Willig as Chief Commercial Officer

Rosetta Genomics announces the appointment of Mark R. Willig as Chief Commercial Officer. In this newly created position, Mr. Willig will be responsible for sales, marketing and market access for Rosetta Genomics’ entire portfolio of high-value diagnostic assays. He will report to Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics.

October 03, 2016
Rosetta Genomics Fortifies Intellectual Property Portfolio with Two New Patent Allowances for its Novel microRNA Platform Technology

Rosetta Genomics announced that the Company has added two new patent allowances to its intellectual property portfolio for its microRNA platform technology. With these new allowances, Rosetta Genomics has 64 granted or allowed patents and 33 patents pending.

September 29, 2016
Rosetta Genomics Enters Distribution Agreement for RosettaGX Reveal in Israel with Rhenium

Rosetta Genomics Ltd., a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that the Company has entered into an exclusive distribution agreement with Rhenium Ltd. for the sales and marketing of RosettaGX Reveal™ (Reveal), the Company’s first-of-its-kind microRNA classifier for indeterminate thyroid nodules, in Israel. Under the terms of the agreement, Rhenium’s exclusivity is contingent on Rhenium meeting certain volume commitments.

September 26, 2016
Rosetta Genomics Reports 2016 Second Quarter Financial Results

Rosetta Genomics Ltd., a leading developer and provider of microRNA-based and other molecular diagnostics, reports financial results for the three and six months ended June 30, 2016.

September 20, 2016
Rosetta Genomics to Host 2016 Second Quarter Financial Results and Business Update Conference Call on September 26, 2016

Rosetta Genomics announced that the Company will file its financial results for the three and six months ended June 30, 2016 on Form 6K with the U.S. Securities and Exchange Commission (“SEC”) after the closing of the U.S. financial markets on September 26, 2016.

September 19, 2016
Rosetta Genomics to Present at Upcoming September Conferences

Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics, will be delivering a corporate overview at the 2016 Aegis Growth Conference taking place September 20-22, 2016 in Las Vegas and at the Ladenburg Thalmann 2016 Healthcare Conference taking place on September 27, 2016 in New York City.

September 07, 2016
RosettaGX Reveal™ Thyroid miRNA Classifier Now available to be Utilized on ThinPrep® Samples

Rosetta Genomics Ltd., announces that the Company’s first-of-its-kind microRNA classifier for indeterminate thyroid nodules, RosettaGX Reveal™ (“Reveal”), is now available to be utilized on ThinPrep® samples. Expected to increase demand by more than 50% over next several months.

August 24, 2016
Rosetta Genomics Selected by a Global Pharmaceutical Company to Supply FISH Testing Services for Clinical Study in Prostate Cancer

Rosetta Genomics announces that the Company has entered into a services agreement with an unnamed global pharmaceutical company to provide Fluorescence in Situ Hybridization (FISH) testing services for a clinical study the pharmaceutical company is conducting in prostate cancer.

August 04, 2016
Rosetta Genomics Expands Molecular Diagnostics Test Menu with Launch of OncoGxSelect™ from Admera Health

New NGS-based Assay Increases Number of Genes Examined for Lung Cancer and Other Solid Tumor Types

July 11, 2016
Rosetta Genomics Receives U.S. Patent Allowance for microRNA-based Ovarian Cancer Treatment

Rosetta Genomics Ltd., announces that the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for U.S. Patent Application No. 14/505,548, entitled “Compositions and methods for treatment of Ovarian Cancer,” which covers a method of treatment for ovarian cancer through the administration of an inhibitor of miR-27a.

July 06, 2016
Rosetta Genomics to Present at Cantor Fitzgerald’s 2nd Annual Healthcare Conference

Rosetta Genomics Ltd. announces that the Company will be participating at Cantor Fitzgerald’s 2nd Annual Healthcare Conference taking place July 12-13, 2016 in New York City. Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics, will deliver the corporate presentation at 2:00 p.m. Eastern time on July 12th.

June 21, 2016
Rosetta Genomics Receives Approval from New York State for HEME FISH-based Assays

Portfolio of Disease-Specific Diagnostic, Prognostic and Predictive Test Panels for Various Hematologic Malignancies Now Available in all 50 States

May 26, 2016
Rosetta Genomics Announces Publication of Data Confirming Analytical Validity of its Novel Thyroid Nodule Classification Assay

RosettaGX Reveal™ is the first commercial test validated to analyze the same thyroid cells on which the initial indeterminate diagnosis was based.

May 23, 2016
Rosetta Genomics Receives Approval from New York State for Four PCR-based Assays

BRAF, EGFR, KRAS and NRAS Mutation Detection Assays Now Available in all 50 States.

May 19, 2016
Rosetta Genomics Reports 2016 First Quarter Results

Record Quarterly Clinical Testing Revenues of $2.6 million - Conference call begins today at 10:00 a.m. Eastern Time - Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today reported financial results for the three months ended March 31, 2016.

May 16, 2016
Rosetta Genomics to Host 2016 First Quarter Financial and Business Update Conference Call on May 19, 2016

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that the company will file its financial results for the three months ended March 31, 2016 on Form 6K with the U.S. Securities and Exchange Commission ("SEC") before the opening of the U.S. financial markets on May 19, 2016.

March 23, 2016
Rosetta Genomics Reports 2015 Full Year Financial Results

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today reported financial results for the 12 months ended December 31, 2015. Revenues reach a record $3.6 million for the fourth quarter, $10.2 million (pro forma) for the year. Conference call begins today at 5:00 p.m. Eastern time

March 17, 2016
Rosetta Genomics to Host Business Update and 2015 Year-End Financial Results Conference Call on March 23, 2016

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that following the close of the U.S. stock market on Wednesday, March 23, 2016, the Company will file its financial results for the 12 months ended December 31, 2015 on Form 20-F with the U.S. Securities and Exchange Commission (“SEC”).

February 29, 2016
Rosetta Genomics Appoints Ana C. Ward as Executive Vice President, Legal and Corporate Development

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces the appointment of Ana C. Ward, Esq. as Executive Vice President, Legal and Corporate Development. Ms. Ward will join Rosetta Genomics as of March 1, 2016 and will work primarily from the Company’s Lake Forest, California facility.

February 25, 2016
Rosetta Genomics Expands Molecular Diagnostics Test Menu with Launch of Three New Product Offerings

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostic testing services, announces the launch of three high-value molecular diagnostic offerings in order to better serve current and prospective clients with a broader molecular test menu. HEME FISH, a portfolio of disease-specific diagnostic, prognostic and predictive test panels for the various hematologic malignancies, BRAF mutation analysis for lung cancer and NRAS mutation analysis for colon cancer are now available through the Company’s Lake Forest, CA-based laboratory, which it acquired in 2015.

February 18, 2016
Rosetta Genomics Receives Approval from New York State for First-of-its-kind Thyroid Cancer Diagnostic Assay

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostic testing services, announces conditional approval status for RosettaGX Reveal™, its novel microRNA classifier for the diagnosis of indeterminate thyroid Fine Needle Aspirate (FNA) smears from the New York State Department of Health (NYSDOH) under the Company’s Molecular Oncology permit. RosettaGX Reveal is the only molecular test in the thyroid market that has been validated in a multicenter, international, blinded study using convenient, routinely prepared cytology slides.

February 08, 2016
Rosetta Genomics to Present at Source Capital's 2016 Disruptive Growth & Healthcare Conference

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that the Company will be participating at Source Capital’s 2016 Disruptive Growth & Healthcare Conference taking place February 10-11, 2016 in New York City. Kenneth A. Berlin, Chief Executive Officer of Rosetta Genomics, will deliver the corporate presentation at 11:15 a.m. Eastern time on February 11th.

February 01, 2016
Rosetta Genomics Announces Agreement with America’s Choice Provider Network for Entire Suite of Diagnostic Tests and Services

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that the Company has entered into an agreement with America’s Choice Provider Network (ACPN®), an independent multispecialty national provider network, that establishes health insurance access to Rosetta’s entire suite of diagnostic tests and services.

January 25, 2016
Rosetta Genomics Granted U.S. Patent Allowance for Use of Gene Expression Signature for Classification of Kidney Tumors

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that the United States Patent and Trademark Office (USPTO) has granted a patent allowance for patent application No. 14/168,981, relating to “Gene Expression Signature for Classification of Kidney Tumors.” The allowed patent claims a method for distinguishing four different types of kidney cancer: oncocytoma, clear cell renal cell carcinoma (RCC), papillary RCC, and chromophobe RCC in a human subject with renal cancer, through the expression profile of 29 microRNAs, and particularly hsa-miR-139-5p, detected by real time polymerase chain reaction (RT-PCR).

January 11, 2016
Rosetta Genomics Granted EPO Patent Allowance for Use of microRNA Molecules for the Treatment of Liver Cancer

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces that the European Patent Office (EPO) has granted a patent allowance for patent application No. 08844596.0, relating to “Targeting microRNAs for the Treatment of Liver Cancer.” This patent is co-owned by Regulus Therapeutics, Inc. (Nasdaq: RGLS). The patent claims chemically-modified, anti-microRNA molecules for use in the treatment of liver cancer, including miR-21, miR-125a, miR-191, miR-210, miR-222, miR-378a, miR-423, and miR-638.

January 06, 2016
Rosetta Genomics Grants Sublicenses to Mirna Therapeutics for microRNA-related Patents for the Development of Oncology Therapeutics

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announces the signing of an agreement with Mirna Therapeutics (NASDAQ: MIRN), for a worldwide sublicense to Rosetta’s patents related to therapeutic uses of certain microRNA technologies. The agreement includes an exclusive sublicense related to Mirna’s MRX34 product candidate, a mimic of naturally occurring microRNA-34 being evaluated in clinical studies for a variety of cancers.

December 14, 2015
Rosetta Genomics and Biocept Advance Collaboration to Proof-of-Concept Studies Aimed at microRNA Profiling of Circulating Tumor Cells to Enhance Lung Cancer Diagnosis

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, and Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to improve the detection and treatment of cancer, announce the successful completion of feasibility studies under a previously announced collaboration to evaluate the use of Biocept's patented microfluidic channel technology to extract circulating tumor cells (CTCs) from blood and Rosetta Genomics' technical expertise and proprietary qRT-PCR platform to characterize microRNAs isolated from those CTCs.

December 01, 2015
Rosetta Genomics Reports Third Quarter 2015 Financial Results

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today reported financial results for the three and nine months ended September 30, 2015.

November 24, 2015
Rosetta Genomics to Present at the LD Micro Main Event

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that it will be presenting at the 8th annual LD Micro Main Event on Wednesday, December 2nd at 8:30 a.m. PST/11:30 a.m. EST. Kenneth A. Berlin, Rosetta’s President and Chief Executive Officer, will be giving the presentation and meeting with investors.

November 12, 2015
Rosetta Provides Update on Performance Data and Launch of RosettaGX Reveal™ (Thyroid microRNA Classifier)

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces additional performance data from the recently-completed, blinded validation study of RosettaGX Reveal™, its microRNA-based diagnostic assay for the classification of indeterminate thyroid nodules.

November 03, 2015
Rosetta Genomics Appoints Dr. Maria Fe Paz as Interim Chief Medical Officer

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces the appointment of Maria Fe Paz, M.D. Ph.D., effective immediately, as a medical affairs consultant in the role of Interim Chief Medical Officer, with plans to transition her to Chief Medical Officer of Rosetta Genomics upon receipt of a valid work visa that supports her planned relocation to the U.S.

October 25, 2015
Rosetta Genomics Reports Financial Results for the First Half of 2015

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today reported financial results for the six months ended June 30, 2015.

October 20, 2015
Positive Performance Data from Validation Study of Rosetta Genomics’ microRNA-based Diagnostic Assay for Thyroid Nodule Classification Presented at the International Thyroid Congress and Annual Meeting of the American Thyroid Association

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that performance and other data from the recently-completed, blinded validation study of its microRNA-based diagnostic assay for the classification of indeterminate thyroid nodules is being presented in a poster entitled “A First-of-its-Kind, microRNA-based Diagnostic Assay for Accurate Thyroid Nodule Classification,” at the 15th International Thyroid Congress (ITC) and 85th Annual Meeting of the American Thyroid Association (ATA).

October 19, 2015
Rosetta Genomics to Host Business Update and Six Month Financials Conference Call on October 27, 2015

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced that following the close of the U.S. stock market on Monday, October 26, 2015, the Company will file its financial results for the six months ended June 30, 2015 on Form 6-K with the U.S. Securities and Exchange Commission (“SEC”). The Form 6-K will include unaudited consolidated financial statements, as well as additional information regarding the Company. The Form 6-K will be available at www.sec.gov and at www.rosettagenomics.com.

October 13, 2015
Rosetta Genomics Raises $8,000,000 in Private Placement

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, today announced it has entered into definitive agreements with investors to purchase an aggregate of $8,000,000 in units, consisting of ordinary shares and warrants, in a private placement. The closing is expected to occur on or about October 16, 2015 and is subject to the satisfaction of customary closing conditions.

October 11, 2015
Rosetta Genomics Launches BRAF Mutation Assay

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces the launch of a molecular test for BRAF mutation analysis to help personalize therapy for melanoma and colon cancer patients. This newest assay will complement its broad offerings so that oncologists can optimize treatment decisions for their cancer patients.

September 30, 2015
Rosetta Genomics to Present at 2015 Aegis Growth Conference

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that Company management will participate in the upcoming 2015 Aegis Growth Conference being held from October 7-9, 2015 at the Encore at Wynn Las Vegas. Kenneth A. Berlin, Rosetta’s President and Chief Executive Officer, will present a corporate overview and update on October 8, 2015 at 11:25 a.m. Pacific Time.

September 29, 2015
Rosetta Genomics to Partner with FNApath to Provide Centralized Laboratory Testing Services for Thyroid Cancer

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that the Company has reached an agreement-in-principle with FNApath of Little Rock, Arkansas, under which Rosetta Genomics will provide endocrinologists initially testing their patients for thyroid cancer with the option of using a pathologist or laboratory of their own choosing, or FNApath, a centralized laboratory with an expertise in diagnosing thyroid cancer. In the event of an indeterminate result, the sample would then be tested with RosettaGx Thyroid Reveal™, the Company’s thyroid neoplasia assay for the differential diagnosis of indeterminate fine needle aspirates (FNAs).

September 22, 2015
Rosetta Genomics Receives U.S. Patent for Treatment of Prostate Cancer

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 14/446,505, titled “Compositions and Methods for the Prognosis and Treatment of Prostate Cancer.”

September 08, 2015
Rosetta Genomics to Present at the 17th Annual Rodman & Renshaw Global Investment Conference

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that Company management will participate in the upcoming 17th Annual Rodman & Renshaw Global Investment Conference being held from September 8-10, 2015 at the St. Regis Hotel in New York City. Ken Berlin, Rosetta’s President and Chief Executive Officer, will present a corporate overview and update on September 9, 2015 at 5:05 p.m. Eastern time.

September 07, 2015
Rosetta Genomics to Present at the 17th Annual Rodman & Renshaw Global Investment Conference

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that Company management will participate in the upcoming 17th Annual Rodman & Renshaw Global Investment Conference being held from September 8-10, 2015 at the St. Regis Hotel in New York City. Ken Berlin, Rosetta’s President and Chief Executive Officer, will present a corporate overview and update on September 9, 2015 at 5:05 p.m. Eastern time.

August 05, 2015
Rosetta Genomics Receives Conditional Approval from New York State for Lung Biomarker

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that the Company was granted conditional approval status for its ROS1 lung cancer biomarker by Fluorescence in situ Hybridization (FISH) assay from the New York State Department of Health (“NYSDOH”) under the Company’s Molecular Oncology permit. New York is the only U.S. state that requires an independent regulatory review process for laboratory-developed tests. With this conditional approval, Rosetta Genomics’ ROS1 by FISH assay is now available in all 50 states. In making the assay available pending final approval, the NYSDOH requires the Company to provide any additional information they request within 60 business days.

August 05, 2015
Rosetta Genomics Receives Accreditation from College of American Pathologists for its Laboratory in California

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that the Accreditation Committee of the College of American Pathologists (CAP) has approved re-accreditation to Rosetta Genomics’, Lake Forest, CA laboratory based on results of a recent on-site inspection as part of the CAP’s Accreditation Programs.

August 05, 2015
Rosetta Genomics Receives Accreditation from College of American Pathologists for its Laboratory in California

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that the Accreditation Committee of the College of American Pathologists (CAP) has approved re-accreditation to Rosetta Genomics’, Lake Forest, CA laboratory based on results of a recent on-site inspection as part of the CAP’s Accreditation Programs.

July 27, 2015
Rosetta Genomics Expands High-Value Molecular Diagnostic Offering with Launch of OncoGxSelect™

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that OncoGxSelect™, Admera Health’s latest next-generation sequencing (NGS) oncology panel, has been approved for clinical use by The New Jersey Department of Health (NJDH). OncoGxSelect™ will be the sixth new product introduced by Rosetta Genomics in 2015. The Company expects to launch its seventh new product, a microRNA-based assay for accurate thyroid nodule classification, by the end of this quarter.

July 07, 2015
Rosetta Genomics Files Pro Forma Financials in Connection with PersonalizeDx Acquisition

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, reports that in connection with its April 2015 acquisition of CynoGen, Inc. (d/b/a PersonalizeDx), it has filed the audited financial statements of PersonalizeDx (PDX) as of and for the years ended December 31, 2014 and 2013 and pro forma financial information as of and for the year ended December 31, 2014, with the U.S. Securities and Exchange Commission. The filing on Form 6-K can be accessed at www.sec.gov and on the Company’s website at www.rosettagenomics.com.

June 30, 2015
Rosetta Genomics Announces Participation in Cantor Fitzgerald’s Inaugural “From Bench to Bedside” Healthcare Conference

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces that company management will participate at the 2015 Inaugural “From Bench to Bedside” Healthcare Conference hosted by Cantor Fitzgerald. The conference will take place at Le Parker Meridien Hotel in New York City on Wednesday, July 8th. Ken Berlin, President and Chief Executive Officer of Rosetta Genomics, will deliver a corporate overview at 2:00 p.m. Eastern time.

May 27, 2015
Rosetta Genomics Launches OncoGxOne™

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announces the commercial launch of OncoGxOne, Admera Health’s next-generation sequencing (NGS) panel that detects a vast number of genetic alterations implicated in cancer to provide clear, concise and actionable clinical recommendations from a single, comprehensive test. OncoGxOne was recently approved as a Laboratory Developed Test and is the fifth new product introduced by Rosetta Genomics in 2015.

May 25, 2015
Rosetta Genomics Announces Selection of First Pilot Project Grant under Strategic Alliance with Moffitt Cancer Center

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular and other diagnostics, announces the selection of the first project grant under its strategic alliance with Moffitt Cancer Center. The funded project is titled, “miRNAs as Determinants and Predictors of Ibrutinib Resistance in Mantle Cell Lymphoma (MCL).” The project will be led by Jianguo Tao, M.D., Ph.D., a renowned hematopathologist and physician-scientist at the Molecular and Chemical Biology Program at Moffitt, and Bijal Shah, M.D., an oncologist in the Experimental Therapeutic Program at Moffitt.

May 15, 2015
Rosetta Genomics Announces Agreement with MultiPlan for its PersonalizeDx Suite of Testing Services

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that PersonalizeDx, a Rosetta Genomics company, has executed a network participation agreement with MultiPlan, Inc. (MultiPlan) for the entire suite of PersonalizeDx testing and services effective July 1, 2015.

May 13, 2015
Rosetta Genomics Launches Two Assays for Bladder Cancer

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular and other diagnostics, announces that the Company will commercially introduce two FGFR3 gene mutation assays; one for diagnostic monitoring using urine samples to detect recurrences of FGFR3-positive lowgrade bladder cancers, and the other in conjunction with Ki67 expression for tissue-based prognostication at initial diagnosis of bladder cancer. Both assays will be introduced at the American Urological Association Annual Meeting (AUA 2015) taking place from May 15-19, 2015 in New Orleans.

May 11, 2015
Data on Rosetta Genomics’ Novel Thyroid Nodule Classification Assay to be Presented at the American Association of Clinical Endocrinologists 24th Annual Scientific and Clinical Congress

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular and other diagnostics, announces that data on the Company’s novel, microRNA-based assay for accurate thyroid nodule classification will be presented at the American Association of Clinical Endocrinologists 24th Annual Scientific and Clinical Congress, being held May 12-15, 2015 in Nashville, Tenn.

April 28, 2015
Rosetta Genomics’ Patent on Therapeutic Use of miR-34a Upheld by European Patent Office in Opposition Proceedings

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular and other diagnostics, announces that the European Patent Office (EPO) has upheld the validity of the Company’s European Patent No. 2126078, following the oral proceedings in the Opposition Proceedings against Rosetta's patent held on April 23, 2015 in Munich, Germany.

April 19, 2015
Rosetta Genomics Announces Data Published in Leukemia Research

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular and other diagnostics, announces that data highlighting its microRNA platform technology was published in Leukemia Research in an article entitled, “microRNA signature is indicative of long term prognosis in diffuse large B cell lymphoma.” The article can be accessed online at www.lrjournal.com.

April 16, 2015
Rosetta Genomics Receives Key U.S. Patent Allowance for its Cancer of Origin Diagnostic Assay

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based assays, FISH testing and other molecular diagnostics, announces receipt of a Notice of Allowance for U.S. Patent Application No. 13/856,190, entitled, “Methods and materials for classification of tissue of origin of tumor samples.”

April 14, 2015
Rosetta Genomics Completes Acquisition of PersonalizeDx

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces the closing of its acquisition of CynoGen, Inc. (d/b/a PersonalizeDx) from Prelude Corporation.

April 08, 2015
Rosetta Genomics to Acquire PersonalizeDx

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces it has agreed to acquire CynoGen, Inc. (d/b/a PersonalizeDx) from Prelude Corporation, a Fjord Ventures portfolio company. The acquisition of PersonalizeDx by Rosetta Genomics is expected to close within the next several weeks and is contingent upon the closing of Prelude’s purchase of PersonalizeDx from a third party.

April 08, 2015
Rosetta Genomics to Acquire PersonalizeDx

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based and other molecular diagnostics, announces it has agreed to acquire CynoGen, Inc. (d/b/a PersonalizeDx) from Prelude Corporation, a Fjord Ventures portfolio company. The acquisition of PersonalizeDx by Rosetta Genomics is expected to close within the next several weeks and is contingent upon the closing of Prelude’s purchase of PersonalizeDx from a third party.

March 25, 2015
Rosetta Genomics Receives Key U.S. Patent Allowance for its Novel Kidney Cancer Test

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces receipt of a Notice of Allowance for U.S. Patent Application No. 13/412,020, entitled, “Gene Expression Signature for Classification of Kidney Tumors.” The patent is owned jointly with Tel Hashomer Medical Research Ltd., the technology transfer company of the Chaim Sheba Medical Center in Israel.

March 24, 2015
Rosetta Genomics to Launch Next-Generation Sequencing Panel from Admera Health

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announces plans to introduce OncoGxOne™, Admera Health’s next-generation sequencing (NGS) panel that detects a vast number of genetic alterations implicated in cancer to provide clear, concise and actionable clinical recommendations from a single, comprehensive test. OncoGxOne™ was recently approved as a Laboratory Developed Test (LDT) and this launch stems from Rosetta Genomics’ collaboration with Admera Health announced on October 30, 2014. OncoGxOne™ will be the fourth new product introduced by Rosetta Genomics in 2015.

March 15, 2015
Rosetta Genomics Reports 2014 Financial Results

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today reported financial results for the 12 months ended December 31, 2014.

March 09, 2015
Rosetta Genomics to Host Business Update and 2014 Year End Financials Conference Call on March 17, 2015

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that following the close of the U.S. stock market on Monday, March 16, 2015, the Company will file its financial results for the year ended December 31, 2014 on Form 20-F with the U.S. Securities and Exchange Commission (“SEC”). The Form 20-F includes audited consolidated financial statements, as well as additional information regarding the Company. Once filed, the Form 20-F will be available at www.sec.gov and at www.rosettagenomics.com.

March 03, 2015
Rosetta Genomics to Present at the 27th Annual ROTH Conference

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that Company management will participate in the upcoming 27th Annual ROTH Conference being held from March 8-11, 2015 at the Ritz Carlton, Laguna Niguel in Dana Point, Calif. Ken Berlin, Rosetta’s President and Chief Executive Officer, will present a corporate overview and update on March 10, 2015 at 5:30 p.m. Pacific time.

February 25, 2015
Rosetta Genomics’ Novel and Differentiated Thyroid Cancer Assay Moves to Advanced Stages of Development

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, provides an update on the development of its microRNA-based assay for the differential diagnosis of thyroid neoplasia, which has the potential to improve clinical management in a cost-effective manner by reducing the number of unnecessary surgeries.

February 16, 2015
Rosetta Genomics Announces Key Patent Allowances in U.S. and Europe

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that the Company received a Notice of Allowance from the United States Patent and Trademark Office for a patent claiming the use of miR-34a for the treatment of p53-associated cancers. In addition, the Company announced its first allowance from the European Patent Office for a patent claiming the specific composition for miR-451, a miR relating to the Company’s Cancer of Unknown Primary (CUP) testing franchise.

February 09, 2015
Rosetta Genomics Receives First Patent Allowance in Japan

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company received a Notice of Allowance from the Japan Patent Office (JPO) for Japanese Patent Application No. 2007-512601, which relates to human miR-92b. The composition of matter patent to be issued claims the sequence of miR-92b and its complement, as well as its use as a probe, including in biochips. miR-92b has been shown to be elevated in cancer and is a key element of the Company’s lead oncology diagnostic, the Rosetta Cancer Origin Test™ (COT).

February 08, 2015
Rosetta Genomics Announces Commercial Partnership with Precipio Diagnostics

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company has entered into a co-promotional commercial partnership with Precipio Diagnostics (“Precipio”) for the sales and marketing of Precipio’s oncology tests, which include bone marrow and peripheral blood testing for hematological malignancies, such as leukemias and lymphomas. These products are being promoted by Rosetta in California, Connecticut, New Jersey, Oklahoma, Texas, Virginia and Washington, D.C., with an expectation to expand nationally over time.

January 19, 2015
Clinician Survey Supporting Value Proposition of the Rosetta Kidney Cancer Test™ Published in the Journal of Kidney Cancer

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the publication of an article in the Journal of Kidney Cancer in support of the use of the Rosetta Kidney Cancer Test?. Titled “Clinicians’ Real World Perceptions of Pre-Nephrectomy Diagnostic Biopsy Performance as a Driver of Reduction in Unnecessary Surgeries in Renal Tumors.”

January 11, 2015
Rosetta Genomics Issues Letter to Shareholders

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the posting of the following Letter to Shareholders from President and Chief Executive Officer Kenneth A. Berlin to the Investors section of the Company’s website at www.rosettagenomics.com.

January 07, 2015
Rosetta Genomics Announces Launch of Admera Health’s Sequencing-Based Oncology Tests

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, announces the commercial launch of the first of the oncology testing services gained through its previously announced collaboration with Admera Health (October 30, 2014). Rosetta Genomics is now offering PGxOne™, a pharmacogenomics test that predicts patients’ responses to drugs based on their personal genetic makeup to avoid adverse effects; and EGFR and KRAS clinical sequencing, which provides genomic analysis of those tumor-based mutations from patient tissue to provide clinically relevant information relating to potential response to therapy, which is helpful for physicians, pathologists and researchers.

November 24, 2014
Rosetta Genomics to Present at LD MICRO “Main Event” Micro-Cap Growth Conference on December 3, 2014

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that Company management will participate in the upcoming LD MICRO “Main Event” Micro-Cap Growth Conference taking place from December 2-4, 2014 in Los Angeles. Kenneth A. Berlin, President and CEO of Rosetta Genomics, will present a corporate overview on Wednesday, December 3, 2014 at 5:00 p.m. PST (8:00 p.m. EST).

November 17, 2014
Rosetta Genomics and Marina Biotech Initiate First Clinical Project Under Strategic Alliance

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, and Marina Biotech, Inc. (OTCQB: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, jointly announced the initiation of the first project under the Strategic Alliance the companies announced on April 2, 2014. The first project will be a clinical study conducted by Rosetta Genomics to identify novel microRNA candidates for the treatment of Duchenne Muscular Dystrophy (DMD).

November 03, 2014
Rosetta Genomics Announces Publication of Data Demonstrating Differentiation of Adrenocortical Carcinomas from Adenomas by microRNA Profiling

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the publication of data relating to the Company’s microRNA platform in the online edition of peer-reviewed journal, “Applied Immunohistochemistry and Molecular Morphology.” The article entitled, “Specific MicroRNAs Differentiate Adrenocortical Adenomas from Carcinomas and Correlate with Weiss Histopathologic System,” highlights the ability of microRNA profiles to differentiate adrenocortical carcinomas from adenomas with very good correlation with the histologic Weiss system for identifying malignancy in adrenocortical tumors (ACTs). This study is part of a collaborative project between Rosetta Genomics and Prof. Meora Feinmesser, M.D., Head of the Institute of Pathology at the Rabin Medical Center in Israel.

October 29, 2014
Rosetta Genomics Partners with Admera Health for the Commercialization of Current and Future Sequencing-Based Oncology Tests

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, announces a collaboration with Admera Health, a spin-off from the clinical services unit of GENEWIZ, Inc., a leading global genomics company. Focused on personalized medicine, Admera Health is a molecular diagnostics company that aims to develop and deliver cost-effective tests that fulfill unmet medical needs, including clinical molecular oncology diagnostics.

October 22, 2014
Rosetta Genomics’ microRNA-based assay for Thyroid Cancer Highlighted in Poster Presentation at 84th Annual Meeting of the American Thyroid Association

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that data in support of the Company’s microRNA-based assay for indeterminate thyroid nodules will be highlighted in a poster presentation entitled, “MicroRNAs as a powerful diagnostic tool for thyroid nodule classification in pre-operative samples,” at the upcoming 84th Annual Meeting of the American Thyroid Association (ATA) taking place from October 29th through November 2nd at the Hotel Del Coronado in Coronado, Calif.

October 20, 2014
Rosetta Genomics and the Institute of Molecular Translational Medicine Partner on Development of Thyroid Cancer Diagnostic

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the initiation by the European Infrastructure for Translational Medicine (EATRIS), of a new public-private translational research project between Rosetta Genomics and the Institute of Molecular Translational Medicine (IMTM) at Palacky University, Olomouc, Czech Republic. The new partnership will work towards the validation and development of a new thyroid cancer diagnostic tool.

September 16, 2014
Rosetta Genomics Reports Financial Results for the First Half of 2014

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today reported financial results for the six months ended June 30, 2014.

September 02, 2014
Rosetta Genomics Initiates Post-Marketing Registry Study of its Cancer Origin Test

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, announces the initiation of the Rosetta Cancer Origin Test™ Patient Registry study (COPR), a two-part global registry attempting to evaluate the impact of the Cancer Origin Test on treatment decisions in patients diagnosed with metastatic cancers or Cancers of Unknown or Uncertain Primary (CUP). COPR will also attempt to track treatments selected, duration of response to therapies, survival and other clinically relevant information including additional diagnostic testing performed.

September 01, 2014
Rosetta Genomics to Participate in September Investor Conferences

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that Company management will participate in two investor conferences in September: the Annual Barrington Research Fall Investment Conference and the Rodman & Renshaw Annual Global Investment Conference.

September 01, 2014
Rosetta Genomics and Moffitt Cancer Center Enter into Strategic Alliance to Develop microRNA-based Cancer Diagnostics

Rosetta Genomics Ltd. (NASDAQ: ROSG), announces that the company has entered into a strategic alliance with Moffitt Cancer Center to discover, develop and commercialize a variety of microRNA-based cancer diagnostics.

August 17, 2014
Rosetta Genomics Expands Management Team with Appointment of Douglas Sites as Executive Vice President of Sales and Marketing

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, announces the appointment of Douglas Sites to the newly-created position of Executive Vice President of Sales and Marketing. Mr. Sites will report to Kenneth A. Berlin, Rosetta’s President and Chief Executive Officer.

July 30, 2014
Rosetta Genomics Announces Agreement with Global Pharmaceutical Company to Advance Efforts in Alzheimer’s Disease Diagnostics

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that it has signed an agreement with a global pharmaceutical company (GPC) in the area of Alzheimer’s disease (AD) diagnostics. Under the agreement, Rosetta will provide its microRNA profiling and other services to assist in the development of a microRNA-based diagnostic for the early detection of AD. Rosetta will leverage the GPC’s expertise in AD as it is considered a pioneer in the development and commercialization of therapeutics for AD.

July 29, 2014
Rosetta Genomics Announces Agreement with Eisai to Advance Efforts in Alzheimer’s Disease Diagnostics

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that it has signed an agreement with Eisai Inc., the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., in the area of Alzheimer’s disease (AD) diagnostics. Under the agreement, Rosetta will provide its microRNA profiling and other services to assist in the development of a microRNA-based diagnostic for the early detection of AD.

June 25, 2014
Rosetta Genomics Receives Notice of Allowance for U.S. Patent for the Prognosis and Treatment of Prostate Cancer

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, announces receipt of a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. Patent Application No. 13/390,995, entitled ”Compositions and Methods for Prognosis and Treatment of Prostate Cancer.” The patent claims cover the expression of miR-205 as an indicator of good prognosis and relates to methods and kits for prognosis of prostate cancer.

June 08, 2014
Rosetta Genomics and Moffitt Cancer Center Enter into Agreement to Advance Development of microRNA-based Cancer Diagnostic

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, announces that the Company has entered into an agreement with Moffitt Cancer Center to advance the development and commercialization of Rosetta’s thyroid neoplasia assay.

April 03, 2014
Rosetta Genomics to Receive U.S. Patent for Cancer Origin Assay

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, today announced that the Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent covering the method of use of a core element of Rosetta Genomics’ microRNA technology in the identification of the tumor of origin in cancer of unknown or uncertain primary and metastatic cancer. The issued claims for U.S. Patent Application No. 13/167,489 is entitled “Gene Expression Signature for Classification of Tissue of Origin of Tumor Samples.”

April 01, 2014
Rosetta Genomics and Marina Biotech Establish Strategic Alliance to Jointly Develop microRNA-based Diagnostics and Therapeutics for Rare Diseases

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, and Marina Biotech, Inc. (Pinksheets: MRNA), a leading nucleic acid-based drug discovery and development company focused on rare diseases, jointly announced that they had established a strategic alliance, wherein the companies will collaborate to identify and develop microRNA-based products designed to diagnose and treat various neuromuscular diseases and dystrophies.

March 30, 2014
Rosetta Genomics Reports 2013 Financial Results

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, today reported financial results for the year ended December 31, 2013.

March 24, 2014
Rosetta Genomics To Host Business Update Conference Call on April 1, 2014

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics, today announced that following the close of the U.S. stock market on Monday, March 31, 2014, the Company will file its Annual Report on Form 20-F for the year ended December 31, 2013 with the U.S. Securities and Exchange Commission (“SEC”). The Form 20-F will include audited annual consolidated financial statements, as well as additional information regarding the Company.

March 23, 2014
Rosetta Genomics Enters Collaboration with Clalit Health Services’ Rabin Medical Center for microRNA-based Assay for Chronic Allograft Dysfunction Following Kidney Transplantation

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, reports that the Company has entered a joint collaboration with Clalit Health Services’ Rabin Medical Center-Beilinson Campus (Petah Tikvah, Israel), a non-profit corporation, for the development of a non-invasive, microRNA-based, assay for the diagnosis of chronic allograft dysfunction (CAD or chronic rejection) following kidney transplantation.

March 20, 2014
Rosetta Genomics’ Cancer Origin Test Highlighted at Landmark CUP Foundation Seminar 2014

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, reports that the Company is sponsoring and participating in the CUP Foundation seminar 2014 taking place from March 21-22 in London, England. This international medical seminar highlights the management, treatment, diagnosis and future perspectives of Cancer of Unknown Primary (CUP) by some of the world’s leading clinicians for CUP and is supported by the European Society for Medical Oncology (ESMO) and the European School of Oncology.

March 11, 2014
Rosetta Genomics Provides Product Pipeline Update

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces details regarding the Company’s plans to advance its proprietary microRNA platform technologies in diagnostics and therapeutics.

March 02, 2014
Rosetta Genomics Announces Publication of Data Correlating miR-150 to Atrial Fibrillation in Patients with Chronic Systolic Heart Failure

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces data from a study of the Company’s microRNA technology was published online in the American Journal of Cardiology in an article entitled, “Relation of Reduced Expression of MiR-150 in Platelets to Atrial Fibrillation in Patients With Chronic Systolic Heart Failure.”

February 25, 2014
Rosetta Genomics to Receive Important U.S. Patent for Oncology Therapeutic

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that the Company received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for a patent claiming Mp53-negative cancer patients. The allowed claims for U.S. Patent Application No. 12/528,690 entitled “Composition and Methods for Modulating Cell Proliferation and Cell Death,” cover a core element of Rosetta Genomics’ microRNA technology in the development of cancer therapeutics associated with non-small cell lung cancer (NSCLC) in p53-negative patients. The allowed patent application is jointly owned with Yeda, the technology transfer company of the Weizmann Institute of Science in Rehovot, Israel.

February 17, 2014
Rosetta Genomics Appoints Kevin Watson as Director, Reimbursement-Managed Care

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the appointment of Kevin Watson to the newly established role of Director, Reimbursement-Managed Care. Mr. Watson is a seasoned reimbursement specialist with nearly 25 years of experience in healthcare policy and reimbursement, managed care marketing, and new product development and commercialization.

February 17, 2014
Rosetta Genomics Executes Agreement With MultiPlan

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company has executed an agreement with Mulitiplan, Inc. (Multiplan) for Rosetta’s healthcare services including the Rosetta Cancer Origin Test™.

November 19, 2013
Rosetta Genomics Expands microRNA Cancer Testing Services Agreement with GeneKor to Include Turkey and Romania

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the expansion of its distribution agreement with GeneKor Medical S.A for the exclusive sales and marketing of the Company’s suite of microRNA-based cancer testing services in Romania and non-exclusive distribution in Turkey, in addition to the original agreement covering Greece. GeneKor is a leading molecular diagnostic service provider based in Greece.

November 05, 2013
Rosetta enomics Reports First Payment from the UK’s National Health Service for the Rosetta Cancer Origin Test™

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the National Health Service (NHS) of the United Kingdom (UK), the world’s largest publicly-funded health service, has made its first payment to the Company for use of the Rosetta Cancer Origin Test™ on a British citizen. The accurate identification of the primary tumor type in primary and metastatic cancer including cancer of unknown or uncertain primary (CUP) is important in guiding clinician treatment decisions to maximize patient outcomes.

September 11, 2013
Rosetta Genomics Granted U.S. Patent Allowance

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the U.S. Patent and Trademark Office granted the Company a Notice of Allowance in connection with U.S. Patent Application Number 12/864,424, titled “Methods and Compositions for Diagnosing Complications of Pregnancy.”

September 08, 2013
Rosetta Genomics Executes Credentialing Agreements With Two National Healthcare Preferred Provider Networks

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company has executed credentialing agreements with FedMed, Inc. (FedMed) and Fortified Provider Network Inc. (FPN) for Rosetta’s Cancer Origin Test™.

August 07, 2013
Rosetta Genomics and Ramot at Tel Aviv University Awarded Grant from Israeli Office of the Chief Scientist to Support Development of microRNA Oncology Therapeutics

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, and Ramot, the technology transfer company of Tel Aviv University, announces that the Israeli Office of the Chief Scientist (OCS) has awarded both companies a grant in the amount of 650,000 NIS (~200,000 USD) to support the first year development of oncology therapeutics utilizing Rosetta Genomics' novel microRNA technology combined with Tel Aviv University's novel delivery system.

August 04, 2013
Rosetta Genomics Announces Launch of New Website

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces the launch of a newly formatted website featuring an interactive, secure physician web portal customized for ordering molecular diagnostic testing services, enhanced and readily accessible information for investors, improved navigation and an easier communication portal with the Company. The new website can be accessed at www.rosettagenomics.com.

June 12, 2013
Medicare Administrator Issues Final Local Coverage Determination for Rosetta Cancer Origin Test™

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that Novitas Solutions, the designated Medicare Administrative Contractor (MAC) for the Company’s microRNA-based diagnostic assays, has issued for notice the final revised Local Coverage Determination (LCD) for Biomarkers in Oncology, which includes the Rosetta Cancer Origin Test™, the Rosetta Lung Cancer Test™ and the Rosetta Kidney Cancer Test™ (formerly miRview® mets2, lung and kidney assays). The LCD will become effective as of August 1, 2013.

June 06, 2013
Rosetta Genomics Executes Credentialing Agreement with Three Rivers Provider Network

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company has executed a credentialing agreement with Three Rivers Provider Network, Inc. (TRPN) of Chula Vista, Calif., for the Rosetta Cancer Origin Test. TRPN is one of the largest supplemental Preferred Provider Organizations (PPO) in the U.S., providing healthcare benefits to more than 10 million members nationwide.

June 05, 2013
Rosetta Genomics Announces Acceptance for Publication by Molecular Cancer of Rosetta Cancer Origin Test Manuscript

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that a manuscript reporting data validating the clinical utility of the Rosetta Cancer Origin Test™ (formerly miRview® mets2) to identify the tumor of origin in Cancer of Unknown or Uncertain Primary (CUP) has been accepted for publication in the peer-reviewed on-line journal Molecular Cancer. The article, titled “Novel microRNA-based assay demonstrates 92% agreement with diagnosis based on clinicopathologic and management data in a cohort of patients with carcinoma of unknown primary,” represents the seventh peer-reviewed publication relating to our CUP assays, and the fifth peer-reviewed publication relating to post market validation studies demonstrating the Cancer Origin Test’s ability to identify tumor origin in CUP with 92% concordance, the highest level of accuracy of any similar study published to date.

June 03, 2013
Rosetta Genomics to Increase the Number of U.S. Sales Territories

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces plans to expand its U.S. commercial footprint from five sales territories currently to 12 territories beginning in July 2013. In addition, the Company reports the successful launch of its new corporate and product branding at the recent American Society of Clinical Oncology Annual Meeting (ASCO 2013).

May 21, 2013
Rosetta Genomics to Present at the Jefferies 2013 Healthcare Conference

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that Kenneth A. Berlin, President and Chief Executive Officer of Rosetta Genomics, will deliver a corporate update at the Jefferies 2013 Healthcare Conference taking place from June 3-6, 2013 in New York City. Mr. Berlin’s presentation will take place on Tuesday, June 4th at 2:00 p.m. Eastern time.

May 19, 2013
Rosetta Genomics Announces Credentialing Agreement with Prime Health Services for miRview mets2

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that the Company has executed a credentialing agreement with Prime Health Services, Inc. (Prime Health), a managed care company that offers a full spectrum of services, including a Preferred Provider Organization (PPO), for the inclusion of Rosetta Genomics’ miRview® mets2 test in Prime Health’s covered products and services.

May 06, 2013
Rosetta Genomics microRNA-based Diagnostic Assays to be Showcased in an Industry Expert Theater Presentation at ASCO’s 2013 Annual Meeting

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announces that the Company’s miRview® suite of oncology diagnostic assays will be highlighted in an “Industry Expert Theater Presentation” at the American Society of Clinical Oncologists (ASCO) 2013 Annual Meeting taking place from May 31-June 4 at McCormick Place Convention Center in Chicago. The “Industry Expert Theater Presentation” is a series of hour-long presentations from industry leaders sharing the latest in oncology practices, products, services and technologies*. Kenneth A. Berlin, Rosetta Genomics’ President and Chief Executive Officer, and E. Robert Wassman, MD, FAAP, FACMG, Rosetta Genomics’ Chief Medical Officer, will deliver a presentation entitled, “Application of microRNAs in Oncology Diagnostics,” on Saturday, June 1st at 3:00 p.m. in the Oncology Professionals Hall.

April 17, 2013
Rosetta Genomics Reaches Settlement Agreement with Sanra Laboratories in Connection with Previous Sale of Parkway Clinical Laboratories

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that the Company has negotiated a settlement with Sanra Laboratories (“Sanra”) in connection with the previous sale of Parkway Clinical Laboratories (“Parkway”) by Rosetta Genomics to Sanra. Under the agreement, Sanra will undertake their best efforts to pay Rosetta Genomics $625,000, in addition to all sums previously paid by them, for total consideration of all their obligations according to the stock purchase agreement entered into in May 2009, of which amount Sanra has already paid $10,000 as an upfront payment.

April 01, 2013
Rosetta Genomics Announces Poster Presentations at AACR Annual Meeting 2013

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that two posters related to the Company’s microRNA-based diagnostic assays will be featured at the American Association for Cancer Research (AACR) Annual Meeting 2013, to be held April 6-10 at the Walter E. Washington Convention Center in Washington, D.C. Both posters will be presented by Mats Sanden, M.D., Medical & Laboratory Director, Rosetta Genomics and will be available for viewing Sunday, April 7 from 1:00-5:00 p.m. local time in the Molecular and Cellular Biology 12 Session in Hall A-C, Poster Section 34.

March 31, 2013
Rosetta Genomics Announces Acceptance for Publication of Kidney Cancer microRNA Diagnostic Manuscript by Molecular Oncology

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces that a manuscript regarding the development and validation of the Company’s microRNA-based diagnostic assay for the classification of renal cell tumors has been accepted for publication by Molecular Oncology. Yael Spector, a scientist from Rosetta Genomics, and Dr. Eddie Fridman, a pathologist and an expert in urological pathology from Sheba Medical Center in Tel-Hashomer, Israel, are the lead authors on the manuscript.

March 24, 2013
Rosetta Genomics To Host Business Update Conference Call on April 10, 2013

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that following the close of the U.S. stock market on Friday, March 22, 2013, the Company filed its Annual Report on Form 20-F for the year ended December 31, 2012 with the U.S. Securities and Exchange Commission (“SEC”). The Form 20-F includes audited annual consolidated financial statements, as well as additional information regarding the Company. The Form 20-F is available at www.sec.gov and at www.rosettagenomics.com.

March 17, 2013
Rosetta Genomics Receives 25th U.S. Patent Allowance

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, announces receipt of a Notice of Allowance from the U.S. Patent Office related to U.S. Patent Application No. 12/517,760 entitled "Nucleic Acids Involved in Viral Infection."

February 13, 2013
Rosetta Genomics Receives Two Key U.S. Patent Allowances

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that the Company has received two notices of allowance from the U.S. Patent and Trademark Office ("USPTO") for Patent Applications 12/661,041 and 12/850,091.

February 06, 2013
Study Validating Ability of microRNAs to Predict Progression of Bladder Cancer Published in British Journal of Urology International

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that data from a study demonstrating the ability of microRNA expression to serve as a biomarker to predict the progression of bladder urothelial carcinoma were published online in the British Journal of Urology International, in an article entitled, “Predicting progression of bladder urothelial carcinoma using microRNA expression.”

January 29, 2013
Rosetta Genomics to be Featured on The Balancing Act® Airing on Lifetime Television Network

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that the Company will be featured on The Balancing Act®, a daily morning talk show on the Lifetime® Television Network devoted to supporting women. The segment featuring Rosetta Genomics will air on the Lifetime Television Network on February 4th, February 27th and March 5th from 7:00-8:00 a.m. Eastern Time.

January 03, 2013
Rosetta Genomics to Present at Sidoti & Company 2013 Micro-Cap Conference

Rosetta Genomics Ltd. (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics, today announced that Kenneth A. Berlin, President and CEO, is scheduled to present a corporate overview at Sidoti & Company's 2013 Micro-Cap Conference on Monday, January 7, 2013 at The Grand Hyatt Hotel in New York City.

Other Filings for ROSG
02/16/17 EFFECT EFFECT
02/16/17 424B3 424B3
02/15/17 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
02/14/17 F-1/A F-1/A
02/14/17 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
02/03/17 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
01/26/17 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
12/20/16 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
12/08/16 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
12/08/16 F-1 F-1
11/28/16 A prospectus disclosing matters covered by form 424B2 and form 424B3. 424B5
11/25/16 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
10/20/16 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
10/14/16 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
10/13/16 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
09/26/16 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
08/22/16 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
08/09/16 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
08/01/16 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
06/24/16 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
06/21/16 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
05/26/16 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
05/19/16 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
03/30/16 424B2 424B2
03/30/16 EFFECT EFFECT
03/23/16 Annual and transition report of foreign private issuers filed pursuant to sections 13 or 15 (d) of the 1934 Act. 20-F
03/23/16 Registration statement for certain foreign private issuers offered pursuant to certain types of transactions. F-3
03/04/16 SC 13D SC 13D
02/25/16 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
01/19/16 SC 13G/A SC 13G/A
01/14/16 SC 13G/A SC 13G/A
01/06/16 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
12/03/15 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
12/03/15 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
12/01/15 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
11/23/15 SC 13G SC 13G
11/23/15 SC 13G SC 13G
11/10/15 424B3 424B3
11/10/15 EFFECT EFFECT
11/03/15 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
10/30/15 Registration statement for certain foreign private issuers offered pursuant to certain types of transactions. F-3
10/27/15 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
10/26/15 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
10/14/15 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
10/14/15 6-K/A 6-K/A
10/02/15 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
09/28/15 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
09/21/15 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
07/08/15 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
07/08/15 A prospectus disclosing matters covered by form 424B2 and form 424B3. 424B5
07/08/15 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
04/14/15 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
03/16/15 Annual and transition report of foreign private issuers filed pursuant to sections 13 or 15 (d) of the 1934 Act. 20-F
02/18/15 A prospectus disclosing matters covered by form 424B2 and form 424B3. 424B5
02/18/15 6-K/A 6-K/A
02/18/15 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
01/12/15 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
11/12/14 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
11/05/14 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
10/24/14 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
10/15/14 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
10/14/14 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
10/01/14 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
09/17/14 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
09/16/14 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
09/08/14 A prospectus disclosing matters covered by form 424B2 and form 424B3. 424B5
09/08/14 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
09/02/14 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
03/31/14 Annual and transition report of foreign private issuers filed pursuant to sections 13 or 15 (d) of the 1934 Act. 20-F
03/31/14 A prospectus disclosing matters covered by form 424B2 and form 424B3. 424B5
03/31/14 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
03/12/14 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
01/13/14 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
12/16/13 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
12/09/13 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
12/06/13 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
09/11/13 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
09/10/13 Registration statement required when securities are offered to employees pursuant to an employee benefit plans. S-8
09/09/13 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
08/21/13 CT ORDER CT ORDER
08/05/13 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
07/29/13 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
07/18/13 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
06/21/13 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
06/13/13 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
05/20/13 CT ORDER CT ORDER
05/14/13 An amendment to a 20-F filing. 20-F/A
03/22/13 A prospectus disclosing matters covered by form 424B2 and form 424B3. 424B5
03/22/13 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
03/22/13 Annual and transition report of foreign private issuers filed pursuant to sections 13 or 15 (d) of the 1934 Act. 20-F
12/27/12 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
12/20/12 424B2 424B2
12/19/12 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
12/19/12 EFFECT EFFECT
12/07/12 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
12/07/12 Registration statement for certain foreign private issuers offered pursuant to certain types of transactions. F-3
11/13/12 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
10/16/12 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
10/12/12 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
10/12/12 Report by foreign issuer under Rules 13a-16 and 15d-16 of the Exchange Act. 6-K
  • How do I contact Investor Relations?

    If you can't find the information you're looking for on our website, please feel free to contact us.

    Investor Relations & Media Contacts:

    LHA
    Anne Marie Fields
    (212) 838-3777
    afields@lhai.com

    Bruce Voss
    (310) 691-7100
    bvoss@lhai.com

    Or write to us here:
    Rosetta Genomics
    3711 Market St. Suite 740
    Philadelphia, PA 19104

  • RosettaGX: Revealing Genomic Answers
  • RosettaGX Reveal Thyroid microRNA Classifier
  • RosettaGX - Providing Cancer Testing Solutions
  • A Patient's Story
  • The RedChip Money Report: Small Stocks Big Money
IP & Pipeline

Intellectual Property

Rosetta Genomics has filed numerous patent applications protecting composition-of-matter for human and viral microRNAs, as well as applications protecting our microRNA extraction protocols and diagnostic methods using microRNAs.

This broad IP position allows Rosetta Genomics to pursue multiple internal product development opportunities. Rosetta Genomics has put in place a unique development engine capable of rapidly advancing multiple diagnostic projects addressing critical unmet needs in cancer and other disease areas.

Strong IP position, which provides access to hundreds of potential microRNA biomarkers

Proprietary discovery, extraction, and quantification technologies enabling us to rapidly expand our pipeline

Extensive collaborations with leading research and knowledge centers provides us with input from the forefront of clinical research as well as access to hundreds of sample types

Click on a button below to learn about our current product portfolio and pipeline.

MARKETED PRODUCTS
  • OncoGxOneTM (NGS solid tumors)
  • OncoGxLungTM (NGS lung tumors)
  • RosettaGX Cancer OriginTM
  • RosettaGX RevealTM (thyroid assay)
  • RosettaGX Lung (mi-LUNGTM)
  • RosettaGX Kidney (mi-KIDNEYTM)
  • FISH (lung, bladder, breast, prostate)
  • FGFR3 mutation analysis: bladder cancer
  • ERG/PTEN: prostate cancer prognostic
PIPELINE
  • Lung cancer prognostic (FISH)
  • Bladder cancer risk stratification (microRNA)
  • Endometrial cancer stratification (microRNA)
  • Alzheimer's Disease-early detection (microRNA)

Patents & Pipelines

Building on its strong patent position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development and commercialization of a full range of microRNA-based diagnostic tools.

CAP-Accredited & CLIA-certified

Rosetta Genomic’s testing services are commercially available through its Philadelphia-based CAP-accredited, CLIA-certified lab.

Corp. Presentations